Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Terapia génica y Hepatología >
Inmunología hepatitis virales >
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista >
Please use this identifier to cite or link to this item:
|Title: ||Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model|
|Author(s) : ||El-Gogo, S. (Susanne)|
Staib, C. (Caroline)
Lasarte, J.J. (Juan José)
Sutter, G. (Gerd)
Adler, H. (Heiko)
|Issue Date: ||2008|
|Publisher: ||John Wiley and Sons|
|Citation: ||El-Gogo S, Staib C, Lasarte JJ, Sutter G, Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J Gene Med 2008 Feb;10(2):177-186.|
|Keywords: ||hepatitis C virus|
Efficient vaccines against hepatitis C virus (HCV) infection are urgently needed. Vaccine development has been hampered by the lack of suitable small animal models to reliably test the protective capacity of immmunization.
We used recombinant murine gammaherpesvirus 68 (MHV-68) as a novel challenge virus in mice and tested the efficacy of heterologous candidate human vaccines based on modified vaccinia virus Ankara or adenovirus, both delivering HCV non-structural NS3 or core proteins.
Recombinant MHV-68 expressing NS3 (MHV-68-NS3) or core (MHV-68-core) were constructed and characterized in vitro and in vivo. Mice immunized with NS3-specific vector vaccines and challenged with MHV-68-NS3 were infected but showed significantly reduced viral loads in the acute and latent phase of infection. NS3-specific CD8+ T cells were amplified in immunized mice after challenge with MHV-68-NS3. By contrast, we did neither detect a reduction of viral load nor an induction of core-specific CD8+ T cells after core-specific immunization.
Our data suggest that the challenge system using recombinant MHV-68 is a highly suitable model to test the immunogenicity and protective capacity of HCV candidate vaccine antigens. Using this system, we demonstrated the usefulness of NS3-specific immunization. By contrast, our analysis rather discarded core as a vaccine antigen.|
|Publisher version (URL): ||http://onlinelibrary.wiley.com/doi/10.1002/jgm.1144/abstract|
|Appears in Collections:||DA - Medicina - Medicina Interna - Artículos de revista|
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.